Turnstone Biologics Inc

Turnstone Biologics Corp. announces a strategic prioritization of its pipeline, reducing its workforce by approximately 60% and extending its cash runway into 2Q 2026, to focus on the clinical advancement of its Phase 1 program, TIDAL-01, which is being evaluated in multiple Phase 1 trials for colorectal cancer, head and neck cancer, and uveal melanoma.

Turnstone Biologics to lay off 60% of workforce, focus on cancer cell therapy. FDA approves Roche's Itovebi for breast cancer, competing with Novartis' Piqray. Gritstone bio files for bankruptcy, in talks for potential buyer. Sanofi halts Denali Therapeutics' Phase 2 MS trial after study failure. Pfizer's Talzenna-Xtandi combo extends prostate cancer survival. Paul Parker joins Flagship Pioneering as managing partner. Zealand Pharma's hypoglycemia drug dasiglucagon rejected by FDA again.

DelveInsight's 'Gene Therapy Competitive Landscape 2024' report covers 250+ companies and 300+ therapies, highlighting key players like Candel Therapeutics, SillaJen Biotherapeutics, and Wuhan Binhui Biotechnology. The report assesses gene therapy products by type, stage, route of administration, and molecule type, and includes inactive pipeline products. Notable therapies in development include ABECMA, ADSTILADRIN, and BREYANZI. Recent clinical trials include Sangamo Therapeutics' ST-920 for Fabry disease and Regenxbio's RGX-202 for Duchenne.